Hui K. Gan, Antony W. Burgess, Adam C. Parslow, Andrew M. Scott
Abstract
Monoclonal antibodies against the Epidermal Growth Factor Receptor (EGFR) are accepted therapies in number of cancer types including colorectal cancer (CRC), and head and neck cancer.
